Friday, April 14, 2023 Daily Archives

Samsung Biologics invests in Swiss ADC firm

by

Samsung Venture Investment Corporation has invested an undisclosed amount in Araris Biotech ahead of a series A funding round. The investment was made by Samsung Life Science Fund, a joint creation between Samsung Biologics and trading company Samsung C&T, which is managed by Samsung Ventures Investment Corporation (Samsung Ventures), an investment corporation that aims to promote the advancement of technologies. “Samsung Biologics plans its investments with Samsung Life Science Fund […] The fund is worth of KRW150 billion [$113 million],”…

April 14, 2023

Avid: Myford expansions to tackle manufacturing backlogs

by

Avid Bioservices has completed its expansion of two cGMP mammalian cell suites at its Myford facility, Tustin, California.  Avid announced the buildout last year. The total manufacturing cost was not disclosed but it was estimated to between $60-70 million. The expansions include upstream and downstream CGMP manufacturing services, increasing capacity for current and future mammalian cell customers, says Avid. The biologics contract development and manufacturing organisation (CDMO) has not disclosed customer details, but it is expected the first use of…

April 14, 2023

Dyadic to take expression platform to Africa

by

Dyadic has expanded its licensing agreement with Rubic One Health to develop and commercialize vaccines and biologics for Africa. Since 2015, Dyadic International has focused on bringing the C1 gene expression platform to the biomanufacturing space, and the firm has struck numerous deals with partners including Luina Bio, Novovet, Alphazyme, and Sanofi. The C1 platform is based on the fungus Myceliophthora thermophila and is used in the industrial enzyme space, where it achieves productivity as high as 80 grams per liter for…

April 14, 2023